Teva Pharm Stock Price, News & Analysis

Teva Pharmaceuticals announced positive results from the Phase 3 RISE study evaluating TV-46000, a long-acting injectable risperidone formulation, aimed at treating schizophrenia. The study showed that TV-46000 significantly prolonged time to relapse and increased clinical stability compared to placebo. Among 544 randomized patients, relapse rates were dramatically lower, with only 9% at week 24 for TV-46000 users versus 28% for placebo. The safety profile was consistent with existing risperidone formulations, indicating potential enhancements in treatment options for patients suffering from this disorder.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has initiated cash tender offers totaling up to $3.5 billion for various series of senior notes due between 2022 and 2024. The goal is to manage and extend the maturity profile of its debt effectively. The offers encompass several note series, including 1.250% and 2.800% Senior Notes due 2023. The offers will expire on November 24, 2021, unless extended. Investors must act before November 9, 2021, for early tender considerations that include a premium of $30.00 per $1,000 of notes.

Teva Pharmaceutical Industries Ltd. reported third-quarter 2021 revenues of $3.9 billion, down 2% year-over-year, with a GAAP EPS of $0.26 and a non-GAAP EPS of $0.59.

Key drivers included strong sales from AJOVY® and AUSTEDO®, while lower revenues from COPAXONE® impacted results. Teva reaffirmed its full-year guidance, anticipating net revenues of $16.0 - $16.4 billion and adjusted EBITDA of $4.8 - $5.1 billion. Cash flow from operations was $529 million with $795 million in free cash flow, reflecting efficient cash management.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced a collaboration with MODAG GmbH to exclusively license and develop the small molecule candidate Anle138b, targeting neurological disorders like multiple system atrophy (MSA) and Parkinson’s disease (PD). The agreement allows Teva to develop and commercialize Anle138b and related compound Sery433, following favorable Phase 1 study results. The collaboration aims to address unmet medical needs in neurodegenerative diseases, potentially impacting thousands of patients annually.

Teva Pharmaceuticals presented new analyses from the COBRA study at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The study, which included data from 99 mothers with multiple sclerosis treated with COPAXONE® (glatiramer acetate) during pregnancy and breastfeeding, found no safety concerns for infants. Specifically, there were no adverse effects on hospitalizations, antibiotic treatments, developmental delays, or growth during the first 18 months. This research addresses significant medical needs concerning treatment safety for women with MS.

U.S. federal judge dismisses AbbVie's trade secret lawsuit against Alvotech, affirming its path to market a biosimilar to Humira. This ruling, delivered on October 6, 2021, supports Alvotech's goal to provide affordable medications. Alvotech has submitted a Biologics License Application for its candidate, AVT02, which aims for FDA interchangeability designation with Humira. Teva Pharmaceuticals is Alvotech's exclusive U.S. commercialization partner for AVT02, enhancing market opportunities in a space valued at US$20 billion globally.

Teva Pharmaceuticals has released research indicating a growing demand among patients for awareness of drug manufacturing origins in Europe. The study reveals that 71% of patients want to know where their medicines are produced, citing concerns over the concentration of manufacturing overseas. 84% of those surveyed support government investments in local pharmaceutical production. The pandemic has highlighted vulnerabilities in global supply chains, necessitating a rebalancing in the pharmaceutical value chain. Teva asserts its commitment to invest close to 1 billion euros in European manufacturing facilities.

Teva Pharmaceutical Industries Ltd. will announce its third-quarter financial results on October 27, 2021, at 7:00 a.m. ET. A conference call will follow at 8:00 a.m. ET, available via phone or a live webcast on Teva's website. Interested parties can join by dialing specific numbers based on their location. Teva is a leader in generic and specialty medicines, with over 3,500 products serving approximately 200 million patients daily.